Alpha-Ketoglutarate (AKG): The TCA Cycle Metabolite With Emerging Longevity Research

What Is Alpha-Ketoglutarate?

Alpha-ketoglutarate (AKG), also known as 2-oxoglutaric acid or oxoglutaric acid, is an endogenous metabolite that sits at the crossroads of several major metabolic pathways. As a key intermediate in the tricarboxylic acid (TCA) cycle, it participates in amino acid catabolism, nitrogen transport, and cellular energy production. AKG is the carbon skeleton left behind after glutamate loses its amino group — a reaction that connects amino acid metabolism to oxidative energy production.

Unlike many studied longevity compounds, AKG is not an exogenous molecule being introduced to biology. It is produced naturally in the body and levels decline measurably with age, a pattern that has attracted significant research interest in the longevity field. Supplemental forms studied in humans include calcium alpha-ketoglutarate (CaAKG) and the arginine-bound form (AAKG), each with distinct pharmacological properties.

Molecular Profile

Mechanism of Action

AKG exerts biological effects through several intersecting mechanisms, which is part of what makes it a compelling research subject.

TCA Cycle and Energy Metabolism. As a TCA intermediate, AKG is converted to succinyl-CoA by the alpha-ketoglutarate dehydrogenase complex (α-KGDH), providing electrons for the electron transport chain. Supplemental AKG can therefore support mitochondrial energy flux, though the degree to which oral AKG increases intracellular AKG concentrations is not fully characterized.

Epigenetic Regulation via α-KG-Dependent Dioxygenases. This is the mechanism drawing the most attention in the longevity field. A large class of enzymes — including the TET DNA demethylases and the Jumonji-domain histone demethylases — require AKG as an obligate co-substrate. These enzymes remove epigenetic marks (DNA methylation, histone methylation) and their activity is directly sensitive to the intracellular AKG/succinate ratio. Because epigenetic drift is considered a primary hallmark of aging, the idea that restoring AKG levels could slow or partially reverse age-related epigenetic changes is mechanistically coherent.

mTOR Pathway Modulation. Animal data suggest AKG may inhibit mTOR (mechanistic target of rapamycin) signaling, a pathway whose suppression is well-established to extend lifespan in model organisms. AKG appears to act via ATP synthase/TOR complex interactions, though the exact pathway differs from rapamycin's mechanism and the dose-response relationships in humans remain uncharacterized.

Nitrogen Scavenging and Ammonia Detoxification. AKG acts as an ammonia scavenger through transamination reactions, converting to glutamine. This may have relevance in states of elevated catabolic activity.

Collagen Synthesis Support. AKG is a required co-factor for prolyl hydroxylase and lysyl hydroxylase enzymes, which hydroxylate proline and lysine residues in collagen precursors. Without adequate AKG, collagen crosslinking is impaired. This mechanism underpins much of the interest in AAKG in sports nutrition contexts.

What the Research Actually Shows

Animal Longevity Studies

The foundational animal data on AKG and aging comes from multiple model organisms.

In C. elegans, AKG supplementation extended median lifespan by approximately 50% in early studies, primarily attributed to mTOR inhibition and α-KGDH modulation. A 2014 study in Nature by Chin and colleagues reported that AKG extended lifespan in nematodes via a mechanism involving the TOR pathway.

In mice, a 2020 study published in Cell Metabolism (Asadi Shahmirzadi et al.) examined CaAKG supplementation in older mice. Female mice receiving CaAKG showed a median lifespan extension of approximately 12%, while frailty scores — measured across multiple domains — were significantly lower in treated animals compared to controls. Importantly, the study used a frailty index of 31 clinical parameters, providing a more multidimensional view of healthspan than lifespan alone. Male mice showed a non-significant trend toward lifespan extension.

A subsequent analysis of the same dataset examined biological aging markers, finding that CaAKG-treated mice showed reduced levels of inflammatory cytokines and methylation markers associated with biological age, suggesting the compound may act on epigenetic aging pathways rather than simply delaying disease.

Human Trials

Human data is considerably more limited, but two studies warrant attention.

The TRIIM trial (Thymus Regeneration, Immunorestoration, and Insulin Mitigation) published in Aging Cell in 2019 (Fahy et al.) used a combination regimen that included CaAKG alongside metformin, DHEA, and growth hormone. The trial reported a reversal of epigenetic age by approximately 2.5 years (as measured by the Horvath epigenetic clock) in 9 treated subjects. However, because the protocol used multiple compounds simultaneously, attributing the epigenetic effect specifically to AKG is not possible from this data.

A small 2023 pilot trial examined CaAKG (1,000 mg/day for 6 months) in adults aged 45–65, measuring biological age via epigenetic clocks and various inflammatory and metabolic markers. The study (Demidenko et al., Aging) reported a mean biological age reduction of approximately 8 years as measured by phenotypic age algorithms, though this was a small, uncontrolled study and the magnitude of effect should be interpreted very cautiously.

Performance and Body Composition

AAKG (arginine alpha-ketoglutarate) has been studied extensively in sports nutrition contexts. A randomized controlled trial by Campbell et al. (2006) found that 4 weeks of AAKG supplementation (12 g/day) improved one-rep-maximum bench press performance and Wingate peak power in resistance-trained men. Other trials have been less consistent, and the nitric oxide precursor effects of arginine rather than AKG itself may explain much of the observed performance benefit.

Anti-Inflammatory Markers

Multiple studies report that AKG reduces circulating levels of pro-inflammatory cytokines including IL-6 and TNF-α in animal models. Whether this translates to clinically meaningful anti-inflammatory effects in humans at supplemental doses is not yet established.

Comparison to Related Longevity Compounds

AKG occupies an interesting niche: unlike rapamycin (a prescription drug with significant immunosuppression risk) and metformin (requiring a prescription in most jurisdictions), CaAKG is available as an over-the-counter supplement at doses used in research. However, its human evidence base is substantially thinner than metformin and comparably thin to NMN.

Research Limitations

Several significant limitations bear emphasis before drawing conclusions from this body of work.

Species translation uncertainty. The dramatic lifespan extensions seen in C. elegans rarely translate proportionally to mammals. The mouse data (12% median lifespan extension in females) is more modest and more relevant, but mouse-to-human translation remains uncertain for any longevity intervention.

Oral bioavailability questions. AKG is a highly reactive metabolite. Whether supplemental oral AKG meaningfully elevates intracellular AKG concentrations — rather than being consumed in peripheral metabolism before reaching target tissues — is not well characterized. The calcium salt form (CaAKG) appears to have better stability than the free acid.

Small, uncontrolled human studies. The Demidenko 2023 pilot study reporting 8-year epigenetic age reduction is an intriguing signal, but the sample was small, lacked a placebo control, and epigenetic clock measurements have high variability. Replication in a larger RCT has not occurred.

Confounder in TRIIM trial. The multi-compound TRIIM regimen prevents any causal attribution to AKG specifically.

Sex differences. The Cell Metabolism mouse study found statistically significant lifespan extension only in females. If this sex-differential effect translates to humans, it would substantially affect how the compound should be studied and potentially used.

Optimal dosing unknown. Human studies have used a range of doses (500 mg to several grams daily). No dose-ranging studies have been conducted in the context of longevity endpoints.

Key Takeaways

1. AKG is an endogenous TCA cycle metabolite whose plasma levels decline approximately 10-fold between young adulthood and old age, making it a biologically plausible longevity target.
2. Animal data — particularly the 2020 Cell Metabolism mouse study — show meaningful healthspan and lifespan extension with CaAKG supplementation, with females showing the most robust effect.
3. AKG's most mechanistically compelling longevity pathway involves its role as a required co-substrate for epigenetic enzymes (TET demethylases, Jumonji demethylases) that remove age-associated methylation marks.
4. A secondary mechanism involves mTOR pathway inhibition, though whether AKG's mTOR effects overlap with or are additive to compounds like rapamycin is not established.
5. Human trial data is limited to small, often uncontrolled studies. The signal is encouraging but insufficient to draw firm efficacy conclusions.
6. AAKG (arginine-bound form) has more robust human data for performance applications, but much of that effect may be attributable to arginine's role as a nitric oxide precursor rather than AKG itself.
7. CaAKG is available as an OTC supplement; the most common research-context dose in humans has been 1,000 mg/day, though optimal dosing is not established.
8. AKG is better understood as an emerging area of longevity research than a validated intervention — further well-controlled RCTs are needed before clinical conclusions are warranted.

This article is for informational and research reference purposes only. Alpha-ketoglutarate as a longevity intervention is not approved or validated for any therapeutic use. The research summarized here represents preliminary findings that require replication in larger, well-controlled human trials. Nothing in this article constitutes medical advice.